Equity Overview
Price & Market Data
Price: $0.98
Daily Change: -$0.0₃6 / 0.06%
Range: $0.941 - $0.995
Market Cap: $61,670,592
Volume: 523,728
Performance Metrics
1 Week: -0.19%
1 Month: -1.14%
3 Months: -27.27%
6 Months: -81.82%
1 Year: -78.13%
YTD: -65.34%
Company Details
Employees: 67
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.